Download PDF
Hamostaseologie 2023; 43(01): 037-043
DOI: 10.1055/a-1987-3559
Review Article

Direct Oral Anticoagulants: Laboratory Challenges and Antidotes

Jan Beyer-Westendorf
1   Department of Medicine I, Universitätsklinikum “Carl Gustav Carus,” Dresden, Germany
,
Christina Köhler
1   Department of Medicine I, Universitätsklinikum “Carl Gustav Carus,” Dresden, Germany
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

The use of direct oral anticoagulants (DOACs) is increasing in patients needing treatment of venous thromboembolism (VTE) and stroke prevention in atrial fibrillation (SPAF). This is due to the net clinical benefit in comparison to vitamin K antagonists (VKAs). The rise in DOAC use is accompanied by a remarkable reduction in heparin and VKA prescriptions. However, this rapid change in anticoagulation patterns brought new challenges to patients, prescribers, laboratories, and emergency physicians. Patients have new liberties concerning nutritional habits and comedication and no longer need frequent monitoring or dose adjustments. Still, they have to comprehend that DOACs are potent anticoagulants that may cause or contribute to bleeding. Challenges for the prescriber include decision pathways for choosing the right anticoagulant and dosage for a specific patient and to change bridging practice in case of invasive procedures. Laboratory personnel are challenged by DOAC due to limited 24/7 availability of specific DOAC quantification tests and by the impact of DOAC on routine coagulation assays and thrombophilia tests. Challenges for the emergency physician result from the increasing age of DOAC anticoagulated patients, the difficulties to establish last intake of DOAC type and dosage, to interpret coagulation test results in emergency situations, and to make decisions for or against DOAC reversal strategies in acute bleeding or urgent surgery. In conclusion, although DOACs make long-term anticoagulation safer and more convenient for patients, DOACs pose challenge to all healthcare providers involved in anticoagulation decisions. The key to correct patient management and optimal outcome therefore lies in education.

Keywords

DOAC - anticoagulation reversal - laboratory testing


Publication History

Received: 26 October 2022

Accepted: 24 November 2022

Article published online:
20 February 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Adam SS, McDuffie JR, Ortel TL, Williams Jr JW. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med 2012; 157 (11) 796-807
    CrossrefPubMedGoogle Scholar
  • 2 Ludwig W-D, Mühlbauer B, Seifert R. Arzneiverordnungs-Report 2021: Springer; 2021
    PubMed
  • 3 Kirchhof P, Benussi S, Kotecha D. et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
    CrossrefPubMedGoogle Scholar
  • 4 Plitt A, Bansilal S. The nonvitamin K antagonist oral anticoagulants and atrial fibrillation: challenges and considerations. J Atr Fibrillation 2017; 9 (05) 1547
    CrossrefPubMedGoogle Scholar
  • 5 Nabauer M, Gerth A, Limbourg T. et al. The registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11 (04) 423-434
    CrossrefPubMedGoogle Scholar
  • 6 Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GYH, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017; 356: j510
    CrossrefPubMedGoogle Scholar
  • 7 Bristol Myers Squibb. Pfizer Inc. Summary of Product Characteristics. Uxbridge; UK: 2020
    Google Scholar
  • 8 Boehringer Ingelheim International GmbH. Summary of Product Characteristics. Ingelheim am Rhein; Germany: 2020
    Google Scholar
  • 9 Daiichi Sankyo Europe GmbH. Summary of Product Characteristics. Munich; Germany: 2020
    Google Scholar
  • 10 Bayer AG. Summary of Product Characteristics. Berlin: Germany; 2020
    PubMedGoogle Scholar
  • 11 Connolly SJ, Ezekowitz MD, Yusuf S. et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
    Google Scholar
  • 12 Giugliano RP, Ruff CT, Braunwald E. et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
    Google Scholar
  • 13 Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol 2013; 29 (7, Suppl): S24-S33
    CrossrefPubMedGoogle Scholar
  • 14 Granger CB, Alexander JH, McMurray JJ. et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    Google Scholar
  • 15 Patel MR, Mahaffey KW, Garg J. et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
    Google Scholar
  • 16 Reilly PA, Lehr T, Haertter S. et al; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63 (04) 321-328
    CrossrefPubMedGoogle Scholar
  • 17 Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 2017; 69 (23) 2779-2790
    CrossrefPubMedGoogle Scholar
  • 18 Yu HT, Yang PS, Jang E. et al. Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with atrial fibrillation. J Am Heart Assoc 2020; 9 (12) e014177
    CrossrefPubMedGoogle Scholar
  • 19 García Rodríguez LA, Martín-Pérez M, Vora P. et al. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK. BMJ Open 2019; 9 (09) e031341
    CrossrefPubMedGoogle Scholar
  • 20 Cho MS, Yun JE, Park JJ. et al. Pattern and impact of off-label underdosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation who are indicated for standard dosing. Am J Cardiol 2020; 125 (09) 1332-1338
    CrossrefPubMedGoogle Scholar
  • 21 Lee KN, Choi JI, Boo KY. et al. Effectiveness and safety of off-label dosing of non-vitamin K antagonist anticoagulant for atrial fibrillation in Asian patients. Sci Rep 2020; 10 (01) 1801
    CrossrefPubMedGoogle Scholar
  • 22 Steffel J, Collins R, Antz M. et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Europace; 2021
    CrossrefGoogle Scholar
  • 23 Mani H, Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des Devel Ther 2014; 8: 789-798
    CrossrefPubMedGoogle Scholar
  • 24 Wunder L, Tittl L, Marten S, Beyer-Westendorf J. DTI/DXI interferences with global coagulation tests in emergency hospital admissions - results of the prospective Dresden NOAC Registry (NCT01588119). Thromb Res 2019; 182: 101-109
    CrossrefPubMedGoogle Scholar
  • 25 Steiner T, Schmitz LS, Grau A, Riess H, Veltkamp R, Poli S. Direkte orale Antikoagulanzien: Was im Notfall zu beachten ist. Dtsch Arztebl Int 2021; 118 (1–2): A-25
    PubMedGoogle Scholar
  • 26 Antovic JP, Skeppholm M, Eintrei J. et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol 2013; 69 (11) 1875-1881
    CrossrefPubMedGoogle Scholar
  • 27 Bonar R, Favaloro EJ, Mohammed S, Pasalic L, Sioufi J, Marsden K. The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 2015; 47 (04) 355-364
    CrossrefPubMedGoogle Scholar
  • 28 Skeppholm M, Hjemdahl P, Antovic JP. et al. On the monitoring of dabigatran treatment in “real life” patients with atrial fibrillation. Thromb Res 2014; 134 (04) 783-789
    CrossrefPubMedGoogle Scholar
  • 29 Douxfils J, Ageno W, Samama CM. et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost 2018; 16 (02) 209-219
    CrossrefPubMedGoogle Scholar
  • 30 Ebner M, Birschmann I, Peter A. et al. Emergency coagulation assessment during treatment with direct oral anticoagulants: limitations and solutions. Stroke 2017; 48 (09) 2457-2463
    CrossrefPubMedGoogle Scholar
  • 31 Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest 2017; 151 (01) 127-138
    CrossrefPubMedGoogle Scholar
  • 32 Yee J, Kaide CG. Emergency reversal of anticoagulation. West J Emerg Med 2019; 20 (05) 770-783
    CrossrefPubMedGoogle Scholar
  • 33 Douxfils J, Dogné JM, Mullier F. et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013; 110 (03) 543-549
    PubMedGoogle Scholar
  • 34 Douxfils J, Lessire S, Dincq AS. et al. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost 2015; 113 (04) 862-869
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23 (02) 138-143
    CrossrefPubMedGoogle Scholar
  • 36 Poli S, Härtig F, Spencer C. et al. Diagnostic accuracy of a novel chromogenic direct thrombin inhibitor assay: clinical experiences for dabigatran monitoring. Thromb Haemost 2017; 117 (12) 2369-2375
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Drouet L, Bal Dit Sollier C, Steiner T, Purrucker J. Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?. Int J Stroke 2016; 11 (07) 748-758
    CrossrefPubMedGoogle Scholar
  • 38 Härtig F, Poli S, Ebner M. et al. Monitoring of low dabigatran concentrations: diagnostic performance at clinically relevant decision thresholds. J Thromb Thrombolysis 2020; 49 (03) 457-467
    CrossrefPubMedGoogle Scholar
  • 39 Gosselin R, Grant RP, Adcock DM. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol 2016; 38 (05) 505-513
    CrossrefPubMedGoogle Scholar
  • 40 Douxfils J, Chatelain B, Chatelain C, Dogné JM, Mullier F. Edoxaban: impact on routine and specific coagulation assays. A practical laboratory guide. Thromb Haemost 2016; 115 (02) 368-381
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Henskens YMC, Gulpen AJW, van Oerle R. et al. Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation. Thromb J 2018; 16: 3
    CrossrefPubMedGoogle Scholar
  • 42 Van Blerk M, Bailleul E, Chatelain B. et al. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey. Thromb Haemost 2015; 113 (01) 154-164
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Platton S, Hunt C. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban. Int J Lab Hematol 2019; 41 (02) 227-233
    CrossrefPubMedGoogle Scholar
  • 44 Monteyne T, De Kesel P, Devreese KMJ. Interference of DOAC stop and DOAC remove in the thrombin generation assay and coagulation assays. Thromb Res 2020; 192: 96-99
    CrossrefPubMedGoogle Scholar
  • 45 Lindhoff-Last E, Birschmann I, Kuhn J. et al; RADOA-Registry Investigators (Reversal Agent use in patients treated with Direct Oral Anticoagulants or vitamin K antagonists Registry). Pharmacokinetics of direct oral anticoagulants in emergency situations: results of the prospective observational RADOA-Registry. Thromb Haemost 2022; 122 (04) 552-559
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Connors JM. Testing and monitoring direct oral anticoagulants. Blood 2018; 132 (19) 2009-2015
    CrossrefPubMedGoogle Scholar
  • 47 Margetić S, Ćelap I, Huzjan AL. et al. DOAC dipstick testing can reliably exclude the presence of clinically relevant DOAC concentrations in circulation. Thromb Haemost 2022; 122 (09) 1542-1548
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 DOASENSE™ GmbH. DOAC Dipstick - product information. 2018 [cited November 23, 2022]. Accessed December 10, 2022 at: https://www.sysmex.de/fileadmin/media/f101/Brochures_Flyer/Packungsbeilage_DOAC_Dipstick.pdf
    PubMedGoogle Scholar
  • 49 Spahn DR, Bouillon B, Cerny V. et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care 2019; 23 (01) 98
    CrossrefPubMedGoogle Scholar
  • 50 Asmis LM, Alberio L, Angelillo-Scherrer A. et al. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 2012; 129 (04) 492-498
    CrossrefPubMedGoogle Scholar
  • 51 Heubner L, Mirus M, Vicent O. et al. Point of care coagulation management in anesthesiology and critical care. Minerva Anestesiol 2022; 88 (7-8): 615-628
    CrossrefPubMedGoogle Scholar
  • 52 Heubner L, Greiner M, Vicent O. et al. Predictive ability of viscoelastic testing using ClotPro® for short-term outcome in patients with severe COVID-19 ARDS with or without ECMO therapy: a retrospective study. Thromb J 2022; 20 (01) 48
    CrossrefPubMedGoogle Scholar
  • 53 Song Y, Wang Z, Perlstein I. et al. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study. J Thromb Haemost 2017; 15 (11) 2125-2137
    CrossrefPubMedGoogle Scholar
  • 54 Zahir H, Brown KS, Vandell AG. et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015; 131 (01) 82-90
    CrossrefPubMedGoogle Scholar
  • 55 Pollack Jr CV, Reilly PA, van Ryn J. et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med 2017; 377 (05) 431-441
    CrossrefPubMedGoogle Scholar
  • 56 Connolly SJ, Crowther M, Eikelboom JW. et al; ANNEXA-4 Investigators. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380 (14) 1326-1335
    CrossrefPubMedGoogle Scholar
  • 57 Benz AP, Xu L, Eikelboom JW. et al; ANNEXA-4 Investigators. Andexanet alfa for specific anticoagulation reversal in patients with acute bleeding during treatment with edoxaban. Thromb Haemost 2022; 122 (06) 998-1005
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 Costa OS, Connolly SJ, Sharma M. et al. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Crit Care 2022; 26 (01) 180
    CrossrefPubMedGoogle Scholar
  • 59 Huttner HB, Gerner ST, Kuramatsu JB. et al. Hematoma expansion and clinical outcomes in patients with factor-Xa inhibitor-related atraumatic intracerebral hemorrhage treated within the ANNEXA-4 trial versus real-world usual care. Stroke 2022; 53 (02) 532-543
    CrossrefPubMedGoogle Scholar
  • 60 Stone L, Merriman E, Hanna M, Royle G, Chan H. Retrospective analysis of the effectiveness of a reduced dose of idarucizumab in dabigatran reversal. Thromb Haemost 2022; 122 (07) 1096-1103
    Article in Thieme ConnectPubMedGoogle Scholar